A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity.
Several T cell immune checkpoint blockade therapies have shown initial successes in multiple cancers. However, significant issues remain, including tumor relapse, severe toxicities, and a lack of efficacy in most patients. SIRPα, commonly known as the "do not eat me signal", is a monocyte...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0321169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849713135547580416 |
|---|---|
| author | Keifer G Kurtz Irina Lebedeva Stephanie A Pierre David Andrew Yu-Rou Liao Daisy Ambriz Olivia Vergnolle Leyi Shen Elizabeth Nyakatura Manuel Baca David A Scheinberg |
| author_facet | Keifer G Kurtz Irina Lebedeva Stephanie A Pierre David Andrew Yu-Rou Liao Daisy Ambriz Olivia Vergnolle Leyi Shen Elizabeth Nyakatura Manuel Baca David A Scheinberg |
| author_sort | Keifer G Kurtz |
| collection | DOAJ |
| description | Several T cell immune checkpoint blockade therapies have shown initial successes in multiple cancers. However, significant issues remain, including tumor relapse, severe toxicities, and a lack of efficacy in most patients. SIRPα, commonly known as the "do not eat me signal", is a monocyte checkpoint cell surface protein. Agents that block the interaction of CD47 with SIRPα have recently shown clinical success in combination with monoclonal antibody therapy to potentiate macrophage phagocytosis of tumors. However, significant toxicities and logistical issues are associated with CD47-targeted agents due to the expression of CD47 on all human cells. In contrast, SIRPα has expression limited to myelomonocytic cells, meaning highly specific SIRPα blocking agents might reduce these toxicities and avoid the target antigen sink. Herein, we generated a high affinity and highly specific SIRPα-targeting monoclonal antibody, F05, that has enhanced SIRPα binding and reduced SIRPβ and SIRPγ binding capacity when compared to other available SIRPα antibodies. Furthermore, we show F05 reprograms immunosuppressive macrophages toward a phagocytic profile in vitro. F05 demonstrated efficacy in solid tumor animal models, providing a rationale for further development of the antibody. |
| format | Article |
| id | doaj-art-2694684b6af5487dbea8a43e3720499e |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-2694684b6af5487dbea8a43e3720499e2025-08-20T03:14:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01205e032116910.1371/journal.pone.0321169A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity.Keifer G KurtzIrina LebedevaStephanie A PierreDavid AndrewYu-Rou LiaoDaisy AmbrizOlivia VergnolleLeyi ShenElizabeth NyakaturaManuel BacaDavid A ScheinbergSeveral T cell immune checkpoint blockade therapies have shown initial successes in multiple cancers. However, significant issues remain, including tumor relapse, severe toxicities, and a lack of efficacy in most patients. SIRPα, commonly known as the "do not eat me signal", is a monocyte checkpoint cell surface protein. Agents that block the interaction of CD47 with SIRPα have recently shown clinical success in combination with monoclonal antibody therapy to potentiate macrophage phagocytosis of tumors. However, significant toxicities and logistical issues are associated with CD47-targeted agents due to the expression of CD47 on all human cells. In contrast, SIRPα has expression limited to myelomonocytic cells, meaning highly specific SIRPα blocking agents might reduce these toxicities and avoid the target antigen sink. Herein, we generated a high affinity and highly specific SIRPα-targeting monoclonal antibody, F05, that has enhanced SIRPα binding and reduced SIRPβ and SIRPγ binding capacity when compared to other available SIRPα antibodies. Furthermore, we show F05 reprograms immunosuppressive macrophages toward a phagocytic profile in vitro. F05 demonstrated efficacy in solid tumor animal models, providing a rationale for further development of the antibody.https://doi.org/10.1371/journal.pone.0321169 |
| spellingShingle | Keifer G Kurtz Irina Lebedeva Stephanie A Pierre David Andrew Yu-Rou Liao Daisy Ambriz Olivia Vergnolle Leyi Shen Elizabeth Nyakatura Manuel Baca David A Scheinberg A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. PLoS ONE |
| title | A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. |
| title_full | A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. |
| title_fullStr | A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. |
| title_full_unstemmed | A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. |
| title_short | A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. |
| title_sort | human antibody specific for sirpα reprograms macrophages and promotes antibody mediated anti cancer activity |
| url | https://doi.org/10.1371/journal.pone.0321169 |
| work_keys_str_mv | AT keifergkurtz ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT irinalebedeva ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT stephanieapierre ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT davidandrew ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT yurouliao ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT daisyambriz ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT oliviavergnolle ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT leyishen ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT elizabethnyakatura ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT manuelbaca ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT davidascheinberg ahumanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT keifergkurtz humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT irinalebedeva humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT stephanieapierre humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT davidandrew humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT yurouliao humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT daisyambriz humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT oliviavergnolle humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT leyishen humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT elizabethnyakatura humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT manuelbaca humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity AT davidascheinberg humanantibodyspecificforsirpareprogramsmacrophagesandpromotesantibodymediatedanticanceractivity |